$CUPR

Super Copper Corp. (CSE: CUPR, OTCQB: CUPPF) said it is mobilizing for a maiden diamond drill program at the El Alto target in Chile, planning up to 15 holes and about 5,000 m to test an 800 m-plus chargeability corridor. It reported Phase 1 geophysics completed at Castilla and said it is fully funded after a March 2026 financing. It also outlined a 15-month biopolymer R&D program for copper processing and remediation.

The article highlights premarket moves in several stocks, including Cuprina Holdings, CEA Industries, Absci and Wendy’s, as of 7:10 a.m. ET. It also notes Cuprina said it received U.S. FDA 510(k) clearance for its MEDIFLY maggot debridement product, according to a company release.

Biotech news roundup: Spero (SPRO) and GSK won FDA approval for Utebzi (tebipenem pivoxil) for complicated UTIs; AbbVie (ABBV) expanded FDA approval of SKINVIVE by JUVÉDERM to neck lines; Cuprina (CUPR) received 510(k) clearance for MEDIFLY maggots. Neumora (NMRA) halted KOASTAL Phase 3 and plans 35% layoffs; enGene (ENGN) cuts ~50%. Biogen (BIIB) agreed to buy RayThera for up to $1B.

The FDA cleared Cuprina Holdings’ second fly species for maggot wound therapy, the company said. Along with Lucilia sericata (cleared since 2004), Cuprina received clearance for Lucilia cuprina (Australian sheep blowfly). Cuprina said it is the only company with FDA clearance for two larvae species; it made no claim of major therapeutic differences.

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

Cuprina Holdings (Cayman) Limited (CUPR) shares rose about 114% on Friday after the company regained compliance with Nasdaq Capital Markets listing requirements, according to the report. The stock traded around $5.16, up 114.12%, after opening at $3.26 and reaching an intraday high of $8.23.

Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares rose 49.3% on Thursday, trading between $3.70 and $3.30 after closing at $2.21. Volume was 3.16M shares, up 2,429% vs. average. Weiss Ratings reaffirmed a “sell (e+)” rating. The company reported Q1 EPS of -$0.40 on revenue of $0.01M.

SINGAPORE, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Cuprina Holdings ( Cayman ) Limited ( Nasdaq: CUPR ) ( "Cuprina" or "the Company" ) , a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Wednesday. The Dow traded down 0.56% to 45,456.80 while the NASDAQ rose 0.12% to 21,905.19. The S&P 500 also rose, gaining, 0.30% to 6,532.40. Information technology shares jumped by 2.2% on ...

U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.17% to 45,632.29 while the NASDAQ rose 0.53% to 21,995.12. The S&P 500 also rose, gaining, 0.64% to 6,554.06.